NOUV — Nouveau Life Pharmaceuticals Income Statement
0.000.00%
HealthcareHighly SpeculativeMicro Cap
- $0.01m
- $0.33m
Annual income statement for Nouveau Life Pharmaceuticals, fiscal year end - June 30th, USD millions except per share, conversion factor applied.
2003 June 30th | 2004 June 30th | 2005 June 30th | 2006 June 30th | 2007 June 30th | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10KSB | 10KSB | 10KSB | 10KSB | 10KSB |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0 | 0 | 0 | 0 | 0 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 0.255 | 0.311 | 0.402 | 0.257 | 0.357 |
Operating Profit | -0.255 | -0.311 | -0.402 | -0.257 | -0.357 |
Net Income Before Taxes | -0.255 | -0.311 | -0.402 | -0.257 | -0.357 |
Provision for Income Taxes | |||||
Net Income After Taxes | -0.255 | -0.311 | -0.402 | -0.257 | -0.357 |
Net Income Before Extraordinary Items | |||||
Net Income | -0.255 | -0.311 | -0.402 | -0.257 | -0.357 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | -0.255 | -0.311 | -0.402 | -0.257 | -0.357 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.012 | -0.014 | -0.001 | -0.01 | -0.013 |
Dividends per Share |